Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Affymax is a biopharmaceutical company that is developing a pipeline of synthetic peptide-based drug candidates against clinically validated targets for the treatment of kidney diseases and cancer. Affymax’s objective is to discover, develop and commercialize novel therapeutics addressing large unmet medical needs. In August 2001, a collaboration of several venture firms created Affymax as an independent company,a spin-out from GlaxoSmithKline. Affymax has leveraged its foundation to become a developer of peptide drugs. HematideÔ, our lead product, is a synthetic peptide-based erythropoiesis-stimulating agent (ESA) in clinical development for anemia due to chronic kidney disease (CKD) and ( www.affymax.com )
Affymax , Inc.
4001 Miranda Ave
Palo Alto, California 94304
USA
Tel: (650) 812-8700
Fax: (650) 424-0832